
Mabion S.A.
Research and experimental development in natural sciences and engineering
Overview
Mabion is a European contract development and manufacturing organization (CDMO) specializing in biologics manufacturing, including drug substance manufacturing, analytics, and fill & finish processes. The company offers end-to-end development services from gene to vial, as well as cell line development and banking. Mabion collaborates with various pharmaceutical companies on projects such as the development of antibody-drug conjugates (ADCs) and analytical method development.
Financials
Revenue history (in m)
Filing timeliness
Financial statements were filed on time, on average 37 days early. All were audited by a statutory auditor.
- 202526/06/2026
- 202409/06/2025
- 202325/06/2024
- 202220/06/2023
- 202127/06/2022
- 202002/07/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Sanctions and PEP lists
| Person | List | Match | |
|---|---|---|---|
| Józef Antoni Banach | Członek organu spółki Skarbu Państwa | confirmed |
Stock quotes
- Open
- PLN 9.47
- High
- PLN 9.58
- Low
- PLN 9.26
- Volume
- 33.08K
- Avg. vol.
- 207.97K
- Market cap
- PLN 151.93M
- P/E ratio
- –
- EPS
- -PLN 3.50
- Shares outstanding
- 16.16M
- 52-week
- PLN 7.68 – 11.22
- Dividend yield
- –
- Dividend
- –
- Ex dividend date
- –
- ISIN
- PLMBION00016
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 881.42k | USD -3.73m | USD -4.03m |
| Q1 2026 | USD 1.23m | USD -2.48m | USD -2.63m |
| Q4 2025 | USD 1.43m | USD -5.06m | USD -5.32m |
| Q3 2025 | USD 1.03m | USD -2.69m | USD -2.70m |
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
News

ESG Week 2026 in Mabion
ESG Week 2026 enabled Mabion employees to learn how to safely care for the environment, the ecosystem and themselves.

Mabion Experts Nominated for the Life Science Sales and Marketing Awards 2026
Read about the Mabion experts who have been nominated for the Life Science Sales and Marketing Awards 2026.

Mabion expert will conduct workshops on digital transformation in GMP
Amanda Jabłońska will lead a webinar and training session for pharmaceutical companies on digital transformation in GMP environment.

Jakub Knurek once again among the TOP 5 Future Leaders at the CPHI Pharma Awards
Jakub Knurek is a Future Leader in the Biopharmaceutical Industry. Our expert was a finalist in the 2026 CPHI Pharma Awards in this category.
Industry
Trademarks
The company holds 1 active trademark registered with the Polish Patent Office. 1 mark has expired or was not registered. The first mark was filed in 2010.
| Mark | Number | Classes | Status | Protected until | |
|---|---|---|---|---|---|
| MABION (word) | Z.375850 | 5 | Protected | Sep 28, 2030 | |
| mabion people and ideas of biotech | Z.381700 | 5 | Proceedings discontinued | – |
| Mark | Protected until | |
|---|---|---|
| MABION (word) | Sep 28, 2030 | |
| mabion people and ideas of biotech | – |
Authorized Representatives
Manner of representation
The following are authorized to make declarations of will on behalf of the company: two members of the management board acting jointly or one member of the management board acting jointly with a commercial proxy.
Supervisory board
Beneficial owners
Mabion is a public company listed on the Warsaw Stock Exchange, so it does not report beneficial owners to the CRBR (Art. 58 of the Polish AML Act). Its shareholders are disclosed in stock-exchange reports.
Bank accounts
Registered as a VAT taxpayer on 2007-06-01.
56 1090 1304 0000 0001 3508 2545
02 1140 1108 0000 3129 5400 1001
14 1090 1304 0000 0001 3458 8116
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| Jan 15, 2025 | Bankruptcy notice | |
| Jan 22, 2020 | Bankruptcy sale | |
| Nov 2, 2018 | Bankruptcy notice | |
| Jun 7, 2010 | Shareholders' meeting convened | |
| Mar 26, 2010 | Shareholders' meeting convened |
Public aid
15 public aid cases recorded, with a total value of $19,962,995.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jan 16, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | –– | Prezes Zakładu Ubezpieczeń Społecznych | |
| Dec 2, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | –– | Prezes Zakładu Ubezpieczeń Społecznych | |
| Dec 2, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | –– | Prezes Zakładu Ubezpieczeń Społecznych |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2021-09-18 | Development of a panel of analytical methods to characterize immunogenicity in a clinical trial for patients suffering from rheumatoid arthritis using rituximab as the medicinal substance. | $538.4K$538,425 | Regional Operational Programme of the Łódź Voivodeship for 2014–2020 | |
| 2017-08-01 | Development of a biotechnological drug through the development of an innovative IgG1-subclass monoclonal antibody with a reduced content of undesirable glycoforms compared with the reference drug, targeting EGFR | $7.4M$7,442,721 | Operational Programme Smart Growth | |
| 2016-11-01 | Development and scaling of an innovative process for manufacturing a therapeutic recombinant monoclonal antibody to enable the industrial implementation of the first Polish biotechnological drug for oncological and autoimmune therapies. | $6.8M$6,834,236 | Operational Programme Smart Growth |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| Integrated permit | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Przedsiębiorstwo Produkcyjno-Handlowe Ewa S.A. | $14,322,437.53 | ewa-sa.pl | ||
| Medicofarma S.A. | $8,530,473.72 | medicofarma.pl | ||
| Nutramatic sp. z o.o. | $6,205,312.16 | nutramatic.pl | ||
| Hemplab sp. z o.o. | $5,520,405.66 | hemplab.pl | ||
| Ever Pharma Poland sp. z o.o. | $3,054,922.01 | everpharma.com | ||
| Elanda Pharma sp. z o.o. | $2,725,664.09 | elanda.pl | ||
| Bioactive T sp. z o.o. | $1,599,993.10 | bioactivet.pl | ||
| Grand Medical Poland sp. z o.o. | $1,394,971.29 | grandmedical.pl | ||
| COS Lab P.S.A. | $1,275,339.79 | coslab.pl | ||
| Celltrion Poland sp. z o.o. | $1,237,076.36 | celltrion.pl |
Change history
| Date | Event | |
|---|---|---|
| 2022-11-29 | Share capital increase (1,616,182.60 PLN → 1,616,232.60 PLN) | |
| 2022-04-20 | Share capital increase (1,616,132.60 PLN → 1,616,182.60 PLN) | |
| 2021-04-02 | Share capital increase (1,373,027.20 PLN → 1,616,132.60 PLN) | |
| 2020-06-18 | Share capital increase (1,372,077.20 PLN → 1,373,027.20 PLN) | |
| 2018-04-30 | Share capital increase (1,180,000.00 PLN → 1,372,077.20 PLN) |
FAQ
Last updated: 2026-08-10